Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 6/6 |
Past Performance | 2/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
ALCOR Stock Overview
Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France.
Rewards
Risk Analysis
Biocorp Production Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €21.60 |
52 Week High | €38.90 |
52 Week Low | €19.00 |
Beta | 1.11 |
1 Month Change | -12.90% |
3 Month Change | -32.92% |
1 Year Change | -8.48% |
3 Year Change | 92.86% |
5 Year Change | 131.26% |
Change since IPO | 137.89% |
Recent News & Updates
What Does The Future Hold For Biocorp Production (EPA:ALCOR)? These Analysts Have Been Cutting Their Estimates
Market forces rained on the parade of Biocorp Production ( EPA:ALCOR ) shareholders today, when the analysts downgraded...
Shareholder Returns
ALCOR | FR Medical Equipment | FR Market | |
---|---|---|---|
7D | -4.0% | -3.7% | 1.7% |
1Y | -8.5% | -4.7% | -4.8% |
Return vs Industry: ALCOR underperformed the French Medical Equipment industry which returned -1.7% over the past year.
Return vs Market: ALCOR underperformed the French Market which returned -5.2% over the past year.
Price Volatility
ALCOR volatility | |
---|---|
ALCOR Average Weekly Movement | 7.5% |
Medical Equipment Industry Average Movement | 5.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in FR Market | 9.3% |
10% least volatile stocks in FR Market | 2.8% |
Stable Share Price: ALCOR is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ALCOR's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 68 | Eric Dessertenne | https://biocorpsys.com |
Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France. The company provides Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Onejet, a motor driven disposable auto-injector designed to deliver viscosity products; Datapen, a motor driven pen injector; and Injay which collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as NEWGUARD, a safety device compatible with various sizes of prefilled syringes; BIOPASS, a reconstitution system with a needle; and closure systems.
Biocorp Production Fundamentals Summary
ALCOR fundamental statistics | |
---|---|
Market Cap | €97.01m |
Earnings (TTM) | €294.23k |
Revenue (TTM) | €10.27m |
319.4x
P/E Ratio9.2x
P/S RatioIs ALCOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALCOR income statement (TTM) | |
---|---|
Revenue | €10.27m |
Cost of Revenue | €3.79m |
Gross Profit | €6.47m |
Other Expenses | €6.18m |
Earnings | €294.23k |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 29, 2022
Earnings per share (EPS) | 0.068 |
Gross Margin | 63.05% |
Net Profit Margin | 2.87% |
Debt/Equity Ratio | 134.4% |
How did ALCOR perform over the long term?
See historical performance and comparisonValuation
Is ALCOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALCOR?
Other financial metrics that can be useful for relative valuation.
What is ALCOR's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | €97.01m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 9.7x |
Enterprise Value/EBITDA | 108.7x |
PEG Ratio | 5.5x |
Price to Sales Ratio vs Peers
How does ALCOR's PS Ratio compare to its peers?
ALCOR PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5x | ||
ALVMG Visiomed Group | 12.5x | n/a | €89.5m |
AMPLI Amplitude Surgical | 1.5x | n/a | €146.8m |
MKEA Mauna Kea Technologies | 4.4x | 31.4% | €37.5m |
ALTER Theradiag | 1.8x | 6.4% | €21.4m |
ALCOR Biocorp Production | 9.4x | 28.3% | €97.0m |
Price-To-Sales vs Peers: ALCOR is expensive based on its Price-To-Sales Ratio (9.4x) compared to the peer average (5x).
Price to Earnings Ratio vs Industry
How does ALCOR's PE Ratio compare vs other companies in the FR Medical Equipment Industry?
Price-To-Sales vs Industry: ALCOR is expensive based on its Price-To-Sales Ratio (9.4x) compared to the French Medical Equipment industry average (1.9x)
Price to Sales Ratio vs Fair Ratio
What is ALCOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9.2x |
Fair PS Ratio | 5.4x |
Price-To-Sales vs Fair Ratio: ALCOR is expensive based on its Price-To-Sales Ratio (9.4x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).
Share Price vs Fair Value
What is the Fair Price of ALCOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALCOR (€22.3) is trading below our estimate of fair value (€85.3)
Significantly Below Fair Value: ALCOR is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is Biocorp Production forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
6/6Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
57.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALCOR's forecast earnings growth (57.9% per year) is above the savings rate (0.3%).
Earnings vs Market: ALCOR's earnings (57.9% per year) are forecast to grow faster than the French market (11.7% per year).
High Growth Earnings: ALCOR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALCOR's revenue (28.3% per year) is forecast to grow faster than the French market (5.4% per year).
High Growth Revenue: ALCOR's revenue (28.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALCOR's Return on Equity is forecast to be high in 3 years time (33%)
Discover growth companies
Past Performance
How has Biocorp Production performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
44.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALCOR has a high level of non-cash earnings.
Growing Profit Margin: ALCOR became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ALCOR has become profitable over the past 5 years, growing earnings by 44% per year.
Accelerating Growth: ALCOR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ALCOR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Return on Equity
High ROE: ALCOR's Return on Equity (9.4%) is considered low.
Discover strong past performing companies
Financial Health
How is Biocorp Production's financial position?
Financial Health Score
2/6Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: ALCOR's short term assets (€6.5M) exceed its short term liabilities (€4.2M).
Long Term Liabilities: ALCOR's short term assets (€6.5M) exceed its long term liabilities (€3.3M).
Debt to Equity History and Analysis
Debt Level: ALCOR's net debt to equity ratio (75.2%) is considered high.
Reducing Debt: ALCOR's debt to equity ratio has increased from 47.4% to 134.4% over the past 5 years.
Debt Coverage: ALCOR's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: ALCOR's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Biocorp Production current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
2.62%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALCOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALCOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALCOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALCOR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALCOR has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
7.3yrs
Average board tenure
CEO
Eric Dessertenne
2.67yrs
Tenure
Mr. Eric Dessertenne has been Chief Executive Officer at Biocorp Production since December 23, 2019 and its Director since September 24, 2021. He had been Chief Operating Officer of Biocorp Production sinc...
Board Members
Experienced Board: ALCOR's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Biocorp Production's employee growth, exchange listings and data sources
Key Information
- Name: Biocorp Production
- Ticker: ALCOR
- Exchange: ENXTPA
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €97.008m
- Shares outstanding: 4.35m
- Website: https://biocorpsys.com
Number of Employees
Location
- Biocorp Production
- Parc Technologique
- Lavaur-la-BEchade
- Issoire
- Auvergne
- 63500
- France
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/17 00:00 |
End of Day Share Price | 2022/08/17 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.